Statewide Universal Newborn Screening for Human Immunodeficiency Virus.
- 1Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.
- 2Department of Biomedical Sciences, State University of New York, Albany, NY 12208, USA.
Abstract
Universal newborn screening for human immunodeficiency virus (HIV) has been mandatory in New York State (NYS) since 1997. The goal of screening is to prevent mother-to-child transmission (MTCT) by using approaches including antiretroviral therapy (ART) in the newborn and lactating mother. Screening is performed using an enzyme-linked immunosorbent assay that detects maternal antibodies in dried blood spots from newborns. From January 2011 through November 2018 and from October 2022 through December 2024, the NYS Newborn Screening Program used the HIV-1 MicroELISA System to screen for anti-HIV-1 antibodies in these samples. Newborns who screened positive were referred to an infectious disease specialist for follow-up. During the period of this study, approximately 2.3 million newborns were screened for HIV-1 antibodies. Amongst 4018 newborns referred for follow-up, MTCT was confirmed in 16 newborns (0.4%), 3930 were uninfected (97.8%), 53 were lost to follow-up or were deceased (1.3%), and 19 newborns were considered to have false-positive HIV results (0.5%). MTCT occurred in one in 144,162 newborns screened during the study period, while one in 577 infants were considered to be at risk of vertical HIV transmission. The numbers of newborns who screened positive for HIV antibodies and were therefore at risk of MTCT as well as MTCT have both fallen from 2011 to 2024. NYS MTCT has been below 1% since 2015. To further reduce transmission risk, factors that contribute to loss to follow-up of infants exposed to HIV should be investigated.
Related
- Consented Universal Newborn Screening for Congenital Cytomegalovirus Infection Using Dried Blood Spot and Dried Saliva Spot Specimens: Implementation and Relative Programmatic Accuracy.
- Human papillomavirus 68 subtypes among people with human immunodeficiency virus and implications for anal screening
- Cost-effectiveness of newborn screening for phenylketonuria and congenital hypothyroidism in Hubei, China.
- Incidental maternal glutaric aciduria type I detection through newborn screening: A case report
- Human immunodeficiency virus infection mimicking very early onset inflammatory bowel disease
BibTeX
@article{tavakoli2026statewide,
title = {{Statewide Universal Newborn Screening for Human Immunodeficiency Virus.}},
author = {Norma P Tavakoli and Melissa Pearce and Richard Sejour and Daniele-Marisa Stansfield and Marilyn Erickson and Rebecca McMahon},
journal = {International journal of neonatal screening},
year = {2026},
month = oct,
doi = {10.3390/ijns12040081},
url = {https://europepmc.org/article/MED/42924758},
note = {CC BY},
}
RIS
TY - JOUR
TI - Statewide Universal Newborn Screening for Human Immunodeficiency Virus.
AU - Norma P Tavakoli
AU - Melissa Pearce
AU - Richard Sejour
AU - Daniele-Marisa Stansfield
AU - Marilyn Erickson
AU - Rebecca McMahon
PY - 2026
DA - 2026/10/02
JO - International journal of neonatal screening
DO - 10.3390/ijns12040081
UR - https://europepmc.org/article/MED/42924758
AB - Universal newborn screening for human immunodeficiency virus (HIV) has been mandatory in New York State (NYS) since 1997. The goal of screening is to prevent mother-to-child transmission (MTCT) by using approaches including antiretroviral therapy (ART) in the newborn and lactating mother. Screening is performed using an enzyme-linked immunosorbent assay that detects maternal antibodies in dried blood spots from newborns. From January 2011 through November 2018 and from October 2022 through December 2024, the NYS Newborn Screening Program used the HIV-1 MicroELISA System to screen for anti-HIV-1 antibodies in these samples. Newborns who screened positive were referred to an infectious disease specialist for follow-up. During the period of this study, approximately 2.3 million newborns were screened for HIV-1 antibodies. Amongst 4018 newborns referred for follow-up, MTCT was confirmed in 16 newborns (0.4%), 3930 were uninfected (97.8%), 53 were lost to follow-up or were deceased (1.3%), and 19 newborns were considered to have false-positive HIV results (0.5%). MTCT occurred in one in 144,162 newborns screened during the study period, while one in 577 infants were considered to be at risk of vertical HIV transmission. The numbers of newborns who screened positive for HIV antibodies and were therefore at risk of MTCT as well as MTCT have both fallen from 2011 to 2024. NYS MTCT has been below 1% since 2015. To further reduce transmission risk, factors that contribute to loss to follow-up of infants exposed to HIV should be investigated.
SN - 2409-515X
ER -